Testing a new influenza vaccine that uses less antigen and can be deployed quickly.
Advanced testing of a hexavalent adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment
This study is testing a new type of flu vaccine that uses tiny particles to boost your immune response, so you can get better protection against different flu strains with smaller doses, making it easier to use during outbreaks.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pop Biotechnologies, INC NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11099904 on NIH RePORTER |
What this research studies
This research focuses on developing an innovative influenza vaccine platform that combines multiple protective components to enhance immune response while using lower doses of the vaccine. The approach involves creating lipid bilayer nanoliposomes that carry important viral proteins, which stimulate the immune system more effectively. By using a unique formulation, the vaccine aims to provide better protection against various strains of influenza, including H1N1 and H3N2. Patients may benefit from a more effective vaccine that can be rapidly deployed during outbreaks.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for influenza complications, such as the elderly, young children, and those with underlying health conditions.
Not a fit: Patients who are not at risk for influenza or those who have already received a different influenza vaccine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and efficient influenza vaccine that requires less antigen and can be quickly distributed during flu seasons or pandemics.
How similar studies have performed: Other research has shown promise in developing nanoparticle-based vaccines, indicating that this approach could be effective.
Where this research is happening
Buffalo, United States
- Pop Biotechnologies, INC — Buffalo, United States (Active)
Researchers
- Principal investigator: Kutscher, Hilliard — Pop Biotechnologies, INC
- Study coordinator: Kutscher, Hilliard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.